February 1, 2017 05:13 PM EST

Aviragen shares plunge as RSV antiviral flunks a small PhIIa study

John Carroll

Editor & Founder

The antiviral biotech Aviragen $AVIR says that its experimental RSV therapy BTA585 flunked a small Phase IIa study in volunteers who had been intranasally …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Aviragen shares plunge as RSV antiviral flunks a small PhIIa study

John Carroll

Editor & Founder

Sign up to read this article for free.

A look at biotech's year of the megaround

After CagriSema, eyes are on Lilly’s oral GLP-1 as next key obesity play

Neumora's major depression drug flunks first of three Phase 3 trials

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Regeneron buys London-based ocular biotech

Eli Lilly seeks to join lawsuit over end of tirzepatide shortage

Avi­ra­gen shares plunge as RSV an­tivi­ral flunks a small PhI­Ia study

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

A look at biotech's year of the megaround

Af­ter Ca­griSe­ma, eyes are on Lil­ly’s oral GLP-1 as next key obe­si­ty play

Neu­mora's ma­jor de­pres­sion drug flunks first of three Phase 3 tri­als

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Re­gen­eron buys Lon­don-based oc­u­lar biotech

Eli Lil­ly seeks to join law­suit over end of tirzepatide short­age

Aviragen shares plunge as RSV antiviral flunks a small PhIIa study

After CagriSema, eyes are on Lilly’s oral GLP-1 as next key obesity play

Neumora's major depression drug flunks first of three Phase 3 trials

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Regeneron buys London-based ocular biotech

Eli Lilly seeks to join lawsuit over end of tirzepatide shortage